

# Ryan Dorton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11402922/publications.pdf>

Version: 2024-02-01

13  
papers

679  
citations

840776

11  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

808  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate. <i>Cancer Research</i> , 2007, 67, 4434-4442.  | 0.9 | 161       |
| 2  | Preclinical Antitumor Activity of a Novel Folate-Targeted Dual Drug Conjugate. <i>Molecular Pharmaceutics</i> , 2007, 4, 659-667.  | 4.6 | 100       |
| 3  | Folate Targeting Enables Durable and Specific Antitumor Responses from a Therapeutically Null Tubulysin B Analogue. <i>Cancer Research</i> , 2008, 68, 9839-9844.  | 0.9 | 86        |
| 4  | Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 918-925. | 2.5 | 65        |
| 5  | In Vivo Structural Activity and Optimization Studies of Folate-Tubulysin Conjugates. <i>Molecular Pharmaceutics</i> , 2009, 6, 1518-1525.  | 4.6 | 60        |
| 6  | Folate-Vinca Alkaloid Conjugates for Cancer Therapy: A Structure-Activity Relationship. <i>Bioconjugate Chemistry</i> , 2014, 25, 560-568.   | 3.6 | 50        |
| 7  | Reducing Undesirable Hepatic Clearance of a Tumor-Targeted Vinca Alkaloid via Novel Saccharopeptidic Modifications. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 336-343.         | 2.5 | 42        |
| 8  | Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic. <i>Scientific Reports</i> , 2018, 8, 8943.  | 3.3 | 40        |
| 9  | Rational Combination Therapy of Vintafolide (EC145) with Commonly Used Chemotherapeutic Drugs. <i>Clinical Cancer Research</i> , 2014, 20, 2104-2114.  | 7.0 | 24        |
| 10 | Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate. <i>Bioconjugate Chemistry</i> , 2019, 30, 1805-1813.  | 3.6 | 22        |
| 11 | High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1998-2008.                                      | 4.1 | 13        |
| 12 | Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1151-1160.                  | 2.3 | 10        |
| 13 | Abstract 832: Pre-clinical development of EC1456: A potent Folate targeted Tubulysin SMDC. <i>Cancer Research</i> , 2014, 74, 832-832.   | 0.9 | 6         |